Abstract
Parkinson's disease (PD) is one of the most common neurodegenerative diseases in the elderly. In recent years increasing evidence supports the pharmaceutical potential of curcumin, a polyphenolic compound in the spice turmeric, against PD. Here we briefly summarize the pharmacological activities of curcumin in vitro and in animal models of PD, including counteracting oxidative stress and inflammation, preventing α-synuclein aggregation and fibrillation, and inhibiting monoamine oxidase B, which endow curcumin with multiple pharmaceutical activities against PD and encourage further studies to investigate its clinical effects.
Keywords: Parkinson's disease, curcumin, antioxidant, anti-inflammation, anti-aggregation.
Related Journals
Current Drug Safety
Current Neuropharmacology
Current Pharmaceutical Design
Current Neurovascular Research
Current Pharmaceutical Analysis
Central Nervous System Agents in Medicinal Chemistry
Current Vascular Pharmacology
Current Alzheimer Research
Current Molecular Pharmacology
Current Aging Science
Related Books
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
New Findings from Natural Substances
Pharmaceutical Chemistry and Production: An Introductory Textbook
Evidence-Based Research in Ayurveda against COVID-19 in Compliance with Standardized Protocols and Practices
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Pharmaceuticals for Targeting Coronaviruses
Medical Applications of Beta-Glucan
Nanotechnology Driven Herbal Medicine for Burns: From Concept to Application
Frontiers in Clinical Drug Research-Dementia
50